Rucaparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Rucaparib (coding:ncit:C137800)

RxNorm: rucaparib (coding:rxcui:1862579, coding:omop:1718850)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) BRCA1 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (2) BRCA1 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (2) BRCA2 oncogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (2) BRCA2 pathogenic variants Ovarian Epithelial Tumor Rucaparib
FDA (2) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (2) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (2) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (2) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Rucaparib
FDA (2) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (2) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (2) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (2) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Rucaparib
FDA (2) BRCA1 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (2) BRCA1 pathogenic variants Prostate Adenocarcinoma Rucaparib
FDA (2) BRCA2 oncogenic variants Prostate Adenocarcinoma Rucaparib
FDA (2) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib